S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NASDAQ:IMMU - Immunomedics Stock Price, Forecast & News

$19.00
-0.35 (-1.81 %)
(As of 01/17/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.89
Now: $19.01▼
$19.68
50-Day Range
$18.02
MA: $20.12▼
$21.77
52-Week Range
$11.55
Now: $19.01▼
$22.22
Volume1.24 million shs
Average Volume1.97 million shs
Market Capitalization$3.67 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IMMU
Previous Symbol
CUSIP45290710
CIK722830
Webhttp://www.immunomedics.com/
Phone973-605-8200

Debt

Debt-to-Equity Ratio0.30
Current Ratio6.51
Quick Ratio6.51

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.16 million
Price / Sales1,701.25
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)($1.03)
Net Income$-273,840,000.00
Net MarginsN/A
Return on Equity-329.61%
Return on Assets-76.70%

Miscellaneous

Employees346
Outstanding Shares193,354,000
Market Cap$3.67 billion
Next Earnings Date2/24/2020 (Estimated)
OptionableOptionable

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:IMMU Rates by TradingView

Why Firing Your Internet Provider Could Save You $19,494 (Ad)


A brand-new technology - code named "Halo-Fi" - could kill off your overpriced cable company for good... beaming lightning-fast internet to your home for an estimated $7 a month.

This is undoubtedly the beginning of the end for "Big 3" internet providers.

Forward-thinking investors in Halo-Fi are lining up to get rich before January 30th.

Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) issued its earnings results on Wednesday, October, 30th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.09. During the same period in the prior year, the business posted ($0.34) earnings per share. View Immunomedics' Earnings History.

When is Immunomedics' next earnings date?

Immunomedics is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Immunomedics.

What price target have analysts set for IMMU?

9 Wall Street analysts have issued 12 month price targets for Immunomedics' shares. Their forecasts range from $16.00 to $40.00. On average, they expect Immunomedics' share price to reach $27.33 in the next year. This suggests a possible upside of 43.8% from the stock's current price. View Analyst Price Targets for Immunomedics.

What is the consensus analysts' recommendation for Immunomedics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics.

What are Wall Street analysts saying about Immunomedics stock?

Here are some recent quotes from research analysts about Immunomedics stock:
  • 1. HC Wainwright analysts commented, "We remind investors that sacituzumab previously achieved a 31% 6.8-month median progression-free survival (mPFS) which, in our view, compares favorably to chemotherapy’s effect in this patient population (10-13% ORR and 3-4 month mPFS). Accordingly, we reiterate our Buy rating, while reducing our 12-month price target from $28 to $26 to account for the removal of the second- line HR+, HER2- mBC setting from our assumptions. IMMU-132 filing resubmission remains on track for early 4Q19." (8/8/2019)
  • 2. According to Zacks Investment Research, "Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. " (7/16/2019)

Has Immunomedics been receiving favorable news coverage?

Media coverage about IMMU stock has been trending somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Immunomedics earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Immunomedics.

Who are some of Immunomedics' key competitors?

What other stocks do shareholders of Immunomedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Celgene (CELG), Synergy Pharmaceuticals (SGYP), Seattle Genetics (SGEN), ImmunoGen (IMGN), NVIDIA (NVDA), Exelixis (EXEL), Iovance Biotherapeutics (IOVA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD) and Netflix (NFLX).

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:
  • Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 48)
  • Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)
  • Mr. Scott A. Canute MBA, Exec. Director (Age 58)
  • Mr. Brendan Delaney, Chief Commercial Officer (Age 44)
  • Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52)

Who are Immunomedics' major shareholders?

Immunomedics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.36%), Peregrine Capital Management LLC (0.36%), Tocqueville Asset Management L.P. (0.02%), Arden Trust Co (0.01%), IFP Advisors Inc (0.00%) and FTB Advisors Inc. (0.00%). Company insiders that own Immunomedics stock include Avoro Capital Advisors Llc, Bryan Ball, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

Which institutional investors are selling Immunomedics stock?

IMMU stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB and Tocqueville Asset Management L.P.. View Insider Buying and Selling for Immunomedics.

Which institutional investors are buying Immunomedics stock?

IMMU stock was bought by a variety of institutional investors in the last quarter, including IFP Advisors Inc, Arden Trust Co and FTB Advisors Inc.. Company insiders that have bought Immunomedics stock in the last two years include Avoro Capital Advisors Llc, Bryan Ball and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

How do I buy shares of Immunomedics?

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $19.01.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $3.67 billion and generates $2.16 million in revenue each year. The biopharmaceutical company earns $-273,840,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Immunomedics employs 346 workers across the globe.View Additional Information About Immunomedics.

What is Immunomedics' official website?

The official website for Immunomedics is http://www.immunomedics.com/.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]


MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  392 (Vote Outperform)
Underperform Votes:  393 (Vote Underperform)
Total Votes:  785
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Market Indexes
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel